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ABSTRACT
A substantial number of ductal carcinoma in situ (DCIS) detected by 
mammography never progress to invasive ductal carcinoma (IDC) and current 
approaches fail to identify low-risk patients not at need of adjuvant therapies. We 
aimed to identify the key miRNAs protecting DCIS from malignant evolution, that may 
constitute markers for non-invasive lesions.
We studied 100 archived DCIS samples, including pure DCIS, DCIS with 
adjacent IDC and pure DCIS from patients with subsequent IDC in contralateral 
breast or no recurrence. A DCIS derived cell line was used for molecular and cellular 
studies.
A genome wide study revealed that pure DCIS has higher miR-126 and miR-218 
expression than DCIS with adjacent IDC lesions or than IDC. The down-regulation 
of miR-126 and miR-218 promoted invasiveness in vitro and, in patients with pure 
DCIS, was associated with later onset of IDC. Survival studies of independent 
cohorts indicated that both miRNAs play a protective role in IDC. The clinical 
findings are in agreement with the miRNAs’ roles in cell adhesion, differentiation 
and proliferation. 
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We propose that miR-126 and miR-218 have a protective role in DCIS and 
represent novel biomarkers for the risk assessment in women with early detection 
of breast cancer.
INTRODUCTION
Breast cancer (BC) is characterized by several 
histological and genetic distinctive features, which lead to 
substantial differences in treatment and clinical outcomes 
[1, 2]. After the advent of screening mammography, 
the proportion of detected early carcinomas increased 
substantially and only 20% of them were expected to 
progress, which implied a high number of over-diagnosed 
lesions [3]. Well-established models of breast cancer 
evolution propose an apparently continuous but non-
obligatory progression through a series of increasingly 
abnormal stages, including the carcinoma in situ. Ductal 
carcinoma in situ (DCIS) represents 20–25% of newly 
diagnosed BC in industrialized countries and up to 40% 
of DCIS lesions progress to invasive carcinoma (IDC) if 
untreated [4]. Similarly to IDC, DCIS is a heterogeneous 
group of breast lesions and the potential for progression 
to invasive carcinoma varies among the molecular 
subtypes [5–9]. The evaluation of clinical biomarkers 
in adjacent DCIS and IDC allowed determining that 
different degrees of aggressiveness characterize DCIS 
lesions with high heterogeneity in the same patient. An 
intra-tumor genetic heterogeneity was also observed in 
adjacent DCIS and IDC, indicating that tumor cells with 
specific genetic and/or epigenetic variants may be selected 
during progression [10–12]. Definitely and at variance 
with IDC, neither traditional classification systems, nor 
molecular characterizations can reliably predict whether 
DCIS will progress. In addition, the intracellular pathways 
that control progression to IDC are still largely unknown, 
making it difficult to identify either robust biomarkers or 
therapeutic targets for DCIS. 
Since present approaches do not allow accurate risk 
stratification, low-risk patients are particularly poorly 
defined in terms of need for adjuvant therapies, with 
subsequent generation of short-term and/or long-term 
effects affecting all-cause mortality. It is then clearly 
emerging that efficient diagnostic assays predicting the risk 
of recurrence and/or progression of each DCIS will play a 
crucial role in the selection of individual therapy [13].
MicroRNAs (miRNAs), conserved single-stranded 
RNA molecules, are non-coding RNAs that post-
transcriptionally regulate gene expression. MiRNAs 
control many cancer hallmarks such as proliferation, 
growth suppression, cell death, angiogenesis, invasion and 
metastasis, but also genome instability and inflammation 
[14]. Although several studies have investigated miRNAs 
in many aspects of breast cancer [15, 16], lesser attention 
has been devoted to the progression of DCIS to IDC. 
In addition, due to tumor heterogeneity, large variation 
exists among the few available miRNA profiles of DCIS, 
performed in very small cohorts and not investigated, 
however, for their functional properties [12, 17, 18].
Our work was aimed to identify miRNAs with an 
effective role in the path/s from in situ to invasive BC. 
This study includes formalin-fixed tumor samples from 
4 DCIS patient groups: a test cohort of pure DCIS and 
three validation cohorts formed by pure DCIS, DCIS with 
adjacent IDC, pure DCIS from patients with, and without 
subsequent IDC in contralateral breast. 
RESULTS
miR-126 and miR-218 are elevated in pure DCIS 
To gain new insights into the miRNomics of DCIS, we 
profiled a collection of 30 pure in situ breast tumors (Cohort 
1) by performing RNAseq on small RNA. The expression 
of 1222 different mature miRNAs was measured across all 
DCIS samples. The miRNA-Seq profiles were compared to 
those of other DCISs from the Farazi’s cohort [17] and of 
IDCs from the TCGA cohort. miR-125b, miR-126, miR-
218 and miR-195 were over-expressed in DCIS vs. IDC 
(P < 0.001) and their over-expression was confirmed in the 
small Farazi DCIS cohort (P < 0.001) (Figure 1A). Among 
these miRNAs we successfully cross-validated miR-126 
and miR-218 when using the samples from the Norway 
study by Sorlie and coworkers [12] (Supplementary Figure 
1). miR-210 was previously reported to be associated with 
DCIS malignant transition [18] and this study confirmed its 
over-expression in DCIS with respect to normal tissues (P < 
0.001), but not to IDC (Figure 1A).
We then studied the levels of validated miR-126 
and miR-218 in patients with DCIS adjacent to invasive 
carcinoma (Figure 1B). Digital RT-PCR after laser capture 
micro-dissection revealed that the DCIS samples with 
adjacent IDC (Cohort 3, n = 30) expressed lower amount 
of miR-126 and of miR-218 than pure DCIS (Cohort 2, 
n = 17) (Figure 1C). 
miR-126 and miR-218 inhibit epithelial-to-
mesenchymal transition and invasion in DCIS-
derived cells
The ability of miR-126 and of miR-218 to regulate 
markers of the epithelial-to-mesenchymal transition 
(EMT) was evaluated in MCF10DCIS cells upon treatment 
with either specific mimics or inhibitors. Two miRNAs 
often lost in breast cancer, miR-125b and miR-195 [16], 
were also included in the assay. The levels of the epithelial 
marker E-cadherin were significantly reduced (P = 
0.008) by miR-126 inhibitor and were increased by the 
over-expression of either miR-126 (P = 0.003) or miR-
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218 (P = 0.02). Concurrently, the inhibition of the two 
miRNAs induced a significant increase (P = 0.02, P = 
0.04, respectively) in the mesenchymal marker Vimentin 
(Figure 2A, 2B). As visualized by plotting the E-cadherin/
Vimentin ratio, high levels of miR-126 and miR-218 
led to the prevalent expression of the epithelial marker 
while their inhibition promoted the predominance of the 
mesenchymal marker (Figure 2C). 
Since E-cadherin is a major component in the 
motility circuit activated during EMT [19], the impact 
of miR-126 and miR-218 on motility and invasion was 
determined in DCIS-derived cells treated with mimics 
or inhibitors. xCELLigence real-time analysis on 
MCF10DCIS cells in which each miRNA was modulated 
showed that the inhibitors of miR-126 or miR-218 
increased the invasion rate through Matrigel (P = 0.03, P 
= 0.04, respectively) while their mimics had the opposite 
effect (P = 0.04, P = 0.03, respectively) (Figure 3A, 
Supplementary Figure 2B). The effects of miR-126 and 
miR-218 were independent, since the invasion scores in 
MCF10DCIS treated with the miRNAs inhibitors were 
additive. Under the same conditions, we failed to detect 
any significant change in the cell proliferation index 
(Supplementary Figure 2A) as well as any effect on cell 
cycle (data not shown). Finally, invasiveness was not 
influenced by co-treatment with inhibitors of other down-
regulated miRNAs in IDC such as miR-125b or miR-195 
(Figure 3B). 
The effects of miR-126 and miR-218 on cell 
invasion were evaluated in the low invasive BT-474 and 
in the highly invasive MDA-MB-231 cells, demonstrating 
that inhibition of each of the two miRNAs increased the 
ability of both cell lines to pass through Matrigel, while 
the use of mimics significantly reduced the invasiveness 
of the MDA-MB-231 cells (Figure 3C).
Clinical significance of miR-126 and miR-218 on 
the outcome of DCIS and IDC patients
To evaluate the prognostic potential of miR-126 and 
miR-218 we investigated their expression in the DCIS 
from a set of rare but highly relevant BC patients (Cohort 
4, n = 23): those that subsequently to DCIS developed a 
contralateral IDC, i.e. the later appearance of an invasive 
Figure 1: The expression of miR-126 and miR-218 is elevated in pure DCIS but not in DCIS adjacent to IDC. (A) 
Box plots showing the difference in expression of miR-125b, miR-126, miR-195, miR-218 and miR-210 in DCIS (Cohort 1, n = 30), 
in the Farazi cohort (DCIS Farazi, n = 7) and in the invasive ductal carcinoma subtypes of the TCGA cohort (Norm: Normal, n = 100; 
HER2: HER2 enriched, n = 56; LumA: Luminal A, n = 226; LumB: Luminal B, n = 120; BL: Basal-like, n = 89; NL: Normal-like, n = 
8). Expression levels of miRNAs (reads per million, rpm) were log2 transformed. (B) Representative haematoxylin and eosin (H&E) 
stained section of breast tumors containing adjacent DCIS and IDC lesions (Cohort 3, n = 30). Bar = 100 µm. (C) Droplet Digital RT-PCR 
analysis of miR-126 and miR-218 in micro-dissected sections of pure DCIS (Cohort 2, n = 17) and adjacent DCIS and IDC (Cohort 3). The 
expression levels of each miRNA are indicated as log2 ratio over its cohort median level. 
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carcinoma in the other breast. This particular set up was 
chosen to define a cohort enriched in high-risk DCIS 
patients. We studied micro-dissected primary unilateral 
pure DCISs from patients who developed a subsequent 
contralateral IDC (“high-risk”, n = 11), pure DCIS from 
patients with no recurrence (“low-risk”, n = 12), and 
unrelated IDC (n = 20). Again, the levels of miR-126 
and miR-218 were significantly higher (P = 0.002, P = 
0.0012, respectively) in indolent DCIS (Figure 4A). The 
levels of both miRNAs in the high-risk DCIS were similar 
Figure 2: miR-126 and miR-218 inhibit the expression of EMT markers in MCF10DCIS cells. (A) Representative Western 
blot analysis of total lysates from MCF10DCIS cells transfected with miRNA inhibitors and mimics, or with their respective negative 
controls (NC). Random sequences were used as negative controls (NC) and to rule out any contribution from miRNAs in serum. Immune 
revelation was performed with anti-E-cadherin and anti-Vimentin antibodies. β-Tubulin was blotted as a control of loaded proteins. 
(B) Relative levels of E-cadherin and Vimentin, normalized on β-Tubulin, as determined by densitometry after Western blot. The mean 
expression level of three separate experiments ± SD is shown. (C) Bar plot of the E-cadherin/Vimentin ratio, as measured in B. The relative 
predominance of E-cadherin over Vimentin upon miRNA treatment established the role of miR-126 and miR-218 in the inhibition of the 
epithelial-to-mesenchymal transition.
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Figure 3: miR-126 and miR-218 inhibit invasion in DCIS and IDC cell lines. (A) xCELLigence-driven dynamic monitoring of 
invasion through Matrigel of MCF10DCIS cells transfected with miRNA mimics or inhibitors, or with negative controls (random sequences 
used as to baseline contributions from miRNAs in serum.). The slope analysis of invasion, that describes the steepness, incline, gradient, 
and changing rate of the Cell Index curves over time, is shown. In each experimental condition, fold changes in the slope compared with 
NC is reported. (B) Slope analysis of cell invasion after treatment with miRNA inhibitors, single or in combination. (C) BT-474 and MDA-
MB-231 cells were transfected with miRNA mimics or inhibitors, or with negative controls (NC), and subjected to dynamic monitoring of 
invasion through Matrigel. In each experimental condition, fold changes in the slope compared with NC is reported. The results are shown 
as the mean of three separate experiments ± SD.
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to those of the IDC. When miR-126 and miR-218 were 
compared in the same sample, almost all high-risk DCIS 
expressed low levels of both miRNAs (Figure 4B). 
To further investigate the clinical relevance of miR-
126 and miR-218 in BC, we measured their association 
with prognosis in three well-characterized IDC cohorts: 
TCGA (n = 918), METABRIC (n = 796) [15], and 
UK cohort from Oxford (n = 210) [21]. miR-218 was 
positively associated with longer RFS or OS in all three 
IDC cohorts (OS METABRIC [95% CI, 0.453–0.770 
RR], P< 0.001; RFS TCGA [95% CI, 0.328–0.938 RR], 
P = 0.03; RFS UK [95% CI, 0.616–0.965 RR], P = 0.02), 
while miR-126 only in one (OS METABRIC [95% CI, 
0.581–0.977 RR], P = 0.03) (Table 1). The Kaplan-Meier 
curves showed that patients with higher miR-218 levels 
had longer relapse-free survival in the TCGA (P = 0.03) 
and UK (P = 0.02) cohorts and longer overall survival in 
METABRIC (P < 0.001) (Supplementary Figure 3). As a 
positive control for the procedure, miR-210 was confirmed 
as indicator of poor prognosis in all cohorts (Table 1). 
Figure 4: Low miR-126 and miR-218 levels in primary pure DCIS correlate with the contralateral development of 
IDC. (A) Box plots showing the expression of miR-126 and mir-218 in DCIS from patients without recurrence (Cohort 4, n = 12), in 
patients who developed a subsequent contralateral IDC (Cohort 4, n = 11) and in unrelated IDC (n = 20). (B) Levels of the two miRNAs in 
the same DCIS from Cohort 4 patients, in which the dotted lines define arbitrary cut-off between high and low levels of miRNA expression. 
miRNA levels were determined using the 2-∆Ct method after normalization to U6 snRNA. 
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Cellular roles of miR-126 and miR-218 in breast 
cancer
The protein coding genes correlated with miR-
126 and miR-218 in BC were identified using Spearman 
correlation, and cross-validation in METABRIC, TCGA, 
and UK breast cancer cohorts. The use of independent 
cohorts, each assayed using different technical platforms, 
ranging from microarrays to RNAseq, ensured a very 
robust assay by removing major technical and platform 
related biases. Successively, we performed a Gene 
Ontology analysis on the correlated coding genes 
(Supplementary File). High miR-126 and miR-218 were 
associated with cell adhesion, with miR-218 impacting on 
the Wnt, Notch, cadherin and integrin signaling pathways. 
Lack of miR-126 or miR-218, on the other hand was 
associated with cell proliferation and mitosis. 
DISCUSSION
Once DCIS is detected, the lesion is excised and 
therapy administered according to the tumor phenotype 
[2, 5]. Although several randomized trials have confirmed 
a >50% reduction in the risk of local recurrence with the 
administration of radiation therapy (RT) compared with 
breast-conserving surgery alone, controversy persists 
regarding whether or not RT is needed in “low-risk” 
patients [7, 8]. Since current approaches do not allow 
accurate risk stratification, low-risk patients are especially 
poorly defined in terms of need for adjuvant therapies, 
which can be associated with short-term and/or long-
term effects affecting all-cause mortality. Thus, molecular 
prognosticators for the risk assessment of DCIS patients 
are highly sought-after. The diverse roles of miRNA 
have been extensively studied in breast cancer, but only 
very few investigations were performed on non-invasive 
lesions [12, 17, 18]. Here, by using next-generation 
sequencing, we identified miR-126 and miR-218 as over-
expressed miRNAs in pure DCIS when compared to 
IDC and normal breast. We validated our results in two 
independent DCIS cohorts [12, 17], confirming that these 
two miRNAs constitute a signature of non-invasive breast 
tumors. Most importantly, we detected high miR-126 
and miR-218 in pure DCIS with no concomitant invasive 
lesions, but not in DCIS with adjacent IDC. Finally, lower 
or no expression of these two miRNAs was also measured 
in primary pure DCIS from patients who went to develop a 
contralateral IDC later in life. Thus, our findings, although 
obtained from relatively small DCIS cohorts, strongly 
indicate that high levels of miR-126 and miR-218 at 
diagnosis characterize low-risk DCIS. 
The presence of miR-126 and miR-218 was also 
associated with better prognosis in three large cohorts 
of patients with invasive breast cancer, reiterating that 
these miRNAs down-modulate malignant properties, as 
shown in vitro for breast and other solid cancers [20, 21]. 
In particular, miR-218 was correlated with longer OS or 
RFS in all cohorts. These results are in agreement with the 
Gene Ontology analysis showing that miR-126 and miR-
218 are involved in cellular adhesion and differentiation, 
and with previously reported data demonstrating the role 
of miR-126 in reducing metastasis of breast cancer [22]. 
At variance with invasive breast tumor cell, in which 
down-regulation of the two miRNAs is related to cell 
cycle and mitosis, we cannot correlate their levels with 
proliferation of non-invasive breast tumors and breast 
tumor derived cells. 
Thus, we propose that the increase of miR-126 and 
miR-218 in DCIS is part of the mechanism activated by 
non-invasive tumor cells to counteract tumorigenesis 
and that the failure of this process, resulting in the down-
modulation of these two miRNAs, may have a role in 
facilitating the progression of DCIS to invasive lesions. 
Modification of methylation levels, related to expression 
of miR-126 and miR-218 in mesothelioma [23] and 
gastric cancer [24], respectively, may be at the basis of 
this phenomenon. 
We tested and validated this hypothesis in vitro, 
using MCF10DCIS cells, the only established DCIS model 
for the study of the malignant evolution of non-invasive 
breast cancer [25, 26]. In addition to MCF10DCIS we 
also studied the BT-474 cell line, derived from a low 
invasive primary tumor [27] and the highly invasive 
MDA-MB-231 cells, in which the tumor suppressor 
role of mir-126 and miR-218 was already demonstrated 
[21, 28]. Using these models we revealed that miR-126 
Table 1: Cox regression analysis of the Overall Survival (OS) and Relapse Free Survival (RFS) of patients enrolled in 
the three most represented IDC cohorts, TCGA (sequencing), METABRIC (microarray) and UK (microarray)
miRNA
OS TCGA 
(n = 918)
OS METABRIC 
(n = 796)
RFS TCGA
(n = 650)
RFS UK
(n = 210)
P-values Relative Risk 
(95% CI)
P -values Relative Risk 
(95% CI)
P -values Relative Risk 
(95% CI)
P -values Relative Risk 
(95% CI)
hsa-miR-126 0.07 1.215
(0.985–1.499)
0.03 0.7531
(0.581–0.977)
0.44 0.818 
(0.493–1.358)
0.32 0.798
(0.512–1.242)
hsa-miR-218 0.43 0.921
(0.751–1.130)
<0.001 0.590
(0.453–0.770)
0.03 0.555
(0.328–0.938)
0.02 0.771
(0.616–0.965)
hsa-miR-210 0.04 1.249
(1.009–1.545)
<0.001 1.621
(1.246–2.110)
0.03 1.817
(1.062–3.111)
<0.001 2.486
(1.554–3.977)
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and miR-218 individually affect the invasion potential of 
these different cell lines. Additionally, the miRNAs’ action 
on MCF10DCIS was cumulative, adding to the evidence 
that their absence in DCIS with invasive propensity was 
simultaneous. 
The EMT program broadly regulates invasion and 
metastasis and it is assumed to play an important role in 
the progression of in situ to invasive breast carcinoma [19, 
29]. The best-characterized alteration in invasion involves 
the loss by carcinoma cells of E-cadherin, a key cell-to-
cell adhesion molecule [19]. Thus we investigated miR-
126 or miR-218 for their ability to affect this process in 
non-invasive BC cells. The inhibition of either miRNA 
lowered the expression of E-cadherin and, concurrently, 
up-regulated Vimentin, indicative of a shift from an 
epithelial to a mesenchymal phenotype. 
Both in vitro assays and Gene Ontology analysis 
of patient samples highlighted the role of miR-126 and 
miR-218 in invasion. Our results are in agreement with 
those by Lesurf et al. [12], who recently reported that 
biological processes that distinguish DCIS from IDC 
are related to the microenvironment. They showed that 
the different subtypes share common features, such as 
cell adhesion, collagen fibril organization, and ECM-
cell receptor interactions. They identified, within each 
subtype, some DCIS that clustered with IDC in numbers 
roughly concordant with estimates of indolent/aggressive 
frequency in DCIS. Nevertheless, they noted that their 
investigation was not designed to study prognosis due to 
small sample size and selection of cases.
Our approach was designed in two stages to identify 
miRNAs related to cancer progression. First, we identified 
and validated differentially expressed miRNAs in DCIS 
compared to IDC, using a patient number larger than 
previously reported in literature, and then we assessed 
the expression of those miRNAs in two special cohorts 
of DCIS patients, one with adjacent IDC and the other 
with subsequent contralateral IDC. Both cohorts included 
progression events, either local or delayed and distant, 
thus encompassing divergent but high-risk types of DCIS 
patients.
In our present work, we aimed to overcome a 
common limitation in the miRNA studies on DCIS: the 
very limited size of the cohorts. First, we started with an 
initial RNAseq cohort of 30 DCIS samples, which is up 
to now the largest published study on miRNA. Second, in 
order to further strengthen our findings, we used additional 
DCIS samples with invasive potential to validate our 
initial miRNA signature. Thus, instead of looking 
at miRNAs specific for BC subtypes, our redundant 
approach allowed us to pinpoint those miRNAs that had a 
robust pattern of expression across multiple DCIS cohorts 
with high invasive features. Although we took special care 
to address the study of small cohorts as outlined above, 
our conclusions could still be affected by cohorts’ size. 
Additionally, while we looked for common mechanisms 
in DCIS, the genotype background and pattern of somatic 
mutations in DCIS were not investigated. Finally, although 
we extended the cellular studies to invasive cells, yielding 
significant results on miRNA roles, repeating the assays 
on more non-invasive cell lines could lead to further 
significant results.
Over-diagnosis is a recognized major problem in 
breast cancer and the lack of prognosticators for early 
lesions hampers the management of patients. miR-126 and 
miR-218 are highly expressed in DCIS with low-invasive 
potential and thus represent important novel biomarkers 
for the risk assessment in women with early detection of 
breast cancer. In addition, up-modulation of these two 
miRNAs could constitute the basis of clinical trials aimed 
to help to make decisions on therapeutic intervention in 
low-risk DCIS patients. 
MATERIALS AND METHODS 
Breast tumor tissues
We used four different cohorts of DCIS patients, 
two with pure DCIS lesions (Cohorts 1 and 2), the third 
with adjacent DCIS and IDC lesions, and the fourth one 
with pure DCIS followed or not by the occurrence of IDC 
in the contralateral breast during follow-up. 30 formalin 
fixed paraffin-embedded (FFPE) samples of primary 
pure DCIS (>70% tumor tissue) were selected from a 
collection of tumors archived at three independent sites: 
Verona, Padua and Rovigo (Cohort 1) and 17 FFPE breast 
tissue sections with pure DCIS were from Pisa Archive 
(Cohort 2). 30 FFPE breast tissue sections with adjacent 
DCIS and IDC lesions were obtained again from the Pisa 
archive (Cohort 3). Finally, 20 FFPE samples of primary 
unilateral pure DCIS from patients with available follow-
up data were from the Verona site and 3 from the Rome 
archive (Cohort 4, n = 23). The Cohort 4 included 11 
patients who developed a contralateral IDC and 12 control 
patients who did not recur. The control was selected on the 
basis of patients’ homogeneity in terms of age (median: 
53, range: 51–55), adjuvant therapy and radiotherapy 
administration. The median follow-up for Cohort 4 was of 
94 months (range: 61–120 months). Twenty unrelated IDC 
samples were used as invasive controls. No samples were 
excluded from the cohorts.
Written informed consent was obtained from all 
patients for their tissue samples to be archived and used for 
research purposes, according to the Helsinki declaration of 
1975.
miRNA-Seq analysis of formalin fixed pure 
DCIS tissues
The miRNA expression profiles of DCIS Cohort 
1 were generated using next-generation sequencing 
(NGS) on the SOLiD platform (ABI) as described in the 
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Supplemental Materials and were compared with those 
published by Farazi et al. [17], and with the IDCs from 
The Cancer Genome Atlas (TCGA, cancergenome.nih.
gov). Successively, we used for validation the raw data for 
DCIS and IDC in the Norway study by Lesurf et al. [12].
Laser-capture micro-dissection and miRNA 
analysis 
Samples with pure DCIS (Cohort 2), with adjacent 
DCIS and IDC (Cohort 3), and with pure DCIS samples 
from patients with follow-up (Cohort 4), as well the IDC 
control samples, were laser micro-dissected (LMD) by 
using the PALM MicroBeam laser microdissector (Carl 
Zeiss) on 2 µm thick sections. For each sample, 200.000–
600.000 μm2 were selected and micro-dissected samples 
were loaded on Maxwell 16 (Promega) to extract RNA, 
following the Maxwell 16 LEV RNA FFPE protocol. 
RNA was reverse-transcribed for miR-126 and miR-
218 using the TaqMan MicroRNA RT kit (Applied 
Biosystems). cDNAs in Cohort 2 and 3 were pre-amplified 
using TaqMan PreAmp protocol (Applied Biosystems) 
and subsequently droplet digital PCR performed using 
the QX100™ System (Bio-Rad) according to the 
manufacturer’s instructions. QuantaSoft (Bio-Rad) was 
used to convert the data into concentrations using Poisson 
distribution. The miRNAs in DCIS samples from Cohort 
4 were quantified by Real-Time qPCR using TaqMan 
MicroRNA assays (Life Technologies) and a Bio-Rad 
CFX96™ system. Statistical analysis was performed using 
the non-parametric median test or Mann-Whitney U test 
for independent samples (SPSS version 21). Two-sided 
tests were always used and P values ≤ .05 were considered 
statistically significant. 
In vitro miRNA activity assays
The human breast cancer-derived cell line 
MCF10DCIS, one of the very few established models 
of DCIS [24], was kindly provided by Dr. Macpherson 
(Beatson Institute for Cancer Research, Glasgow, UK). 
Cells were grown in Dulbecco’s modified Eagle’s medium 
and Ham’s F-12 medium (1:1, v/v) (DMEM F-12, Gibco 
Laboratories) supplemented with 5% horse serum and 1% 
penicillin-streptomycin (Gibco Laboratories) at 37° C in 5% 
CO2. The BT-474 breast cancer-derived cell line was from 
ICLC (Genova, I) and was maintained in RPMI 1640 growth 
medium (Gibco) supplemented with 10% FBS, 1 mM Na 
pyruvate and 0.01 mg/ml bovine insulin. MDA-MB-231 
cells were from the American Type Culture Collection 
(ATCC) and were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco Laboratories) supplemented with 
10% FBS.
All cell lines were monthly tested for mycoplasm 
and other contaminations and quarterly subjected to cell 
identification by single-nucleotide polymorphism.
For specific modulation of miRNAs, transient 
transfections were carried out with synthetic inhibitors 
or mimics for miRNAs (miRVana miRNA, Life 
Technologies) and Lipofectamine 2000 in Opti-MEM I 
medium (Gibco) without serum. Random sequences were 
used as negative controls and to check for any contribution 
from miRNAs in serum. The transfected cells were 
incubated at 37° C for 48 hours prior to immunochemical 
and cellular assays.
Total cells lysates (25 μg protein) were separated 
on 7.5% polyacrylamide SDS gels and blotted to 
nitrocellulose membranes (GE Healthcare Life Science). 
The membranes were incubated with antibodies directed 
against Vimentin and β-tubulin (Sigma) and E-cadherin 
(Santa Cruz Biotechology), and revealed with ECL 
(PerkinElmer). The chemiluminescent bands were 
detected on an ImageQuant™ LAS 4000 imager and 
densitometry was performed with Image Quant TL (GE 
Healthcare). Statistical analysis of Western blot data was 
performed using the non-parametric median test or Mann–
Whitney U test for independent samples. Two-sided tests 
were always used and P values ≤ 0.05 were considered 
statistically significant. 
Cell proliferation and invasiveness were evaluated 
with the xCELLigence Real-Time Cell Analyzer System 
(Roche) that monitors cell events by measuring electrical 
impedance, as previously reported [30]. To measure cell 
proliferation, 2500 cells/well were plated and signal 
detection enabled every 15 min up to 96 hours. For the 
invasion assay, 4000 cells/well were seeded onto the 
top chambers covered with a layer of Matrigel (BD 
Biosciences) diluted 1:20. The bottom chambers were 
filled with medium containing 10% serum and the signal 
was detected every 15 min for a total of 24 hours. 
miRNA expression and outcome in ductal 
carcinoma 
The data from the METABRIC study of Dvinge 
et al. [15], accession number EGAS00000000122, were 
obtained from the European Genome-phenome Archive 
(EGA), and the normalized miRNA profiles (accession 
number EGAD00010000438) were studied in relation 
with overall survival (OS, n = 796). The TCGA miRNA 
profiles for primary BCs were obtained from TCGA data 
portal (OS, n = 918). The data from the Buffa’s study 
[31] (UK cohort, n = 210) were obtained from the GEO 
repository (GSE22216). All miRNA profiles were quantile 
normalized. The association between continuous miRNA 
expression and survival times was carried out using 
univariable Cox regression. The Kaplan–Meier survival 
curves with the cases divided by miRNA expression 
(median cut) were constructed for survival times up to 
120 months and the log-rank test was used to assess their 
significance. The analyses were performed using BRB-
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Array Tools-R/BioConductor (version 4.4) and SPSS 
(version 21). No samples were excluded from the cohorts.
To pinpoint the cellular roles of miR-126 and miR-218 
in breast cancer, we performed a Gene Ontology analysis 
of the correlated gene sets using the Panther Classification 
System (as described in Supplementary Materials). 
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